Journal of Clinical Oncology · 1989 · 73 citations · 16 references
MedicineOncologyPharmacologyCancer Drug Toxicity ManagementChemotherapyOncology PharmacotherapyConcurrent ChemoradiationSupportive Care In CancerChemotherapy Dose IntensityDisease-free Survival AnalysisDisease-free Survival AssessmentRelapse-free SurvivalSalvage
The association between dose intensity of chemotherapy with the rate of complete remission (CR), the duration of disease-free survival (DFS), and overall survival (OS) was separately analyzed for 67 patients initially treated with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP), and for 75 patients in relapse following radiotherapy who had received MOPP as a salvage regimen. In both groups of patients, the fraction of the total dose of mechlorethamine delivered in all cycles divided by the planned dose for six cycles was strongly associated with OS (P = .002 for patients receiving initial MOPP and P = .02 for the salvage group, respectively). B symptoms were independent of drug-derived variables associated with OS (corresponding P values .03 for initial MOPP and .004 for the salvage group). The predictive value of mechlorethamine dosage with regard to OS was retained in an analysis restricted to the patients receiving greater than or equal to six cycles of chemotherapy. In the initial chemotherapy group, mechlorethamine dosage was associated with attainment of CR but none of the variables tested was predictive of DFS. In the salvage chemotherapy group, mechlorethamine dosage was associated with attainment of CR and duration of DFS as well. The results emphasize that, besides tumor characteristics, optimal dosage of chemotherapy is of great importance for survival.
16
Covariance Analysis of Censored Survival Data
N. E. Breslow · Biometrics · 1974 · 1.8K citations
Dose: A critical factor in cancer chemotherapy
Emil Frei, George P. Canellos · The American Journal of Medicine · 1980 · 848 citations
Medicine, Oncology, Pharmacology +14
Twenty years of MOPP therapy for Hodgkin's disease.
Dan L. Longo, Robert C. Young, Margaret Wesley et al. · Journal of Clinical Oncology · 1986 · 439 citations
Average relative dose intensity and the impact on design of clinical trials.
W M Hryniuk · PubMed · 1987 · 229 citations